It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
MicroRNAs (miRNAs) associated with Argonaute proteins (AGOs) regulate gene expression in mammals. miRNA 3’ ends are subject to frequent sequence modifications, which have been proposed to affect miRNA stability. However, the underlying mechanism is not well understood. Here, by genetic and biochemical studies as well as deep sequencing analyses, we find that AGO mutations disrupting miRNA 3’ binding are sufficient to trigger extensive miRNA 3’ modifications in HEK293T cells and in cancer patients. Comparing these modifications in TUT4, TUT7 and DIS3L2 knockout cells, we find that TUT7 is more robust than TUT4 in oligouridylating mature miRNAs, which in turn leads to their degradation by the DIS3L2 exonuclease. Our findings indicate a decay machinery removing AGO-associated miRNAs with an exposed 3’ end. A set of endogenous miRNAs including miR-7, miR-222 and miR-769 are targeted by this machinery presumably due to target-directed miRNA degradation.
3′ end of microRNAs binds to the PAZ domain of Argonaute (AGO) proteins. Here the authors show that terminal nucleotidyltransferases TUT4/7 and exonuclease DIS3L2 induce tailing and decay of 3’ end exposed-microRNAs in AGO PAZ mutant expressing- or cancer cells.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details



1 Center for Cancer Research, National Cancer Institute, RNA Mediated Gene Regulation Section; RNA Biology Laboratory, Frederick, USA (GRID:grid.417768.b) (ISNI:0000 0004 0483 9129)
2 Center for Cancer Research, National Cancer Institute, RNA Mediated Gene Regulation Section; RNA Biology Laboratory, Frederick, USA (GRID:grid.417768.b) (ISNI:0000 0004 0483 9129); Zhejiang Chinese Medical University, School of Basic Medicine, Hangzhou, China (GRID:grid.268505.c) (ISNI:0000 0000 8744 8924)
3 Center for Cancer Research, National Cancer Institute, RNA Mediated Gene Regulation Section; RNA Biology Laboratory, Frederick, USA (GRID:grid.417768.b) (ISNI:0000 0004 0483 9129); Chinese Academy of Agricultural Sciences, State Key Laboratory of Veterinary Biotechnology and Heilongjiang Province Key Laboratory for Laboratory Animal and Comparative Medicine, Harbin Veterinary Research Institute, Harbin, China (GRID:grid.410727.7) (ISNI:0000 0001 0526 1937)